Alliance for Pandemic Preparedness

January 11, 2021

Continuation versus Discontinuation of Renin–Angiotensin System Inhibitors in Patients Admitted to Hospital with COVID-19: A Prospective, Randomised, Open-Label Trial

Category:

Topic:

Keywords (Tags):

A prospective, randomized, open-label trial concluded that renin–angiotensin system inhibitors, which are commonly used to treat hypertension, could safely be continued in patients hospitalized with COVID-19. Between March 31 and August 20, 2020, 152 participants were randomly assigned to either continue or discontinue renin–angiotensin system inhibitor therapy. 16 (21%) participants in the continuation arm versus 14 (18%) in the discontinuation arm required intensive care unit admission or invasive mechanical ventilation, and 11 (15%) of 75 participants in the continuation arm versus 10 (13%) in the discontinuation arm died. 29 (39%) participants in the continuation arm and 28 (36%) participants in the discontinuation arm had at least one adverse event. 

Cohen et al. (Jan 7, 2021). Continuation versus Discontinuation of Renin–Angiotensin System Inhibitors in Patients Admitted to Hospital with COVID-19: A Prospective, Randomised, Open-Label Trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(20)30558-0